Skip to main content

Progyny, Inc. (NASDAQ:PGNY) EVP Sells $123,579.47 in Stock

Last updated on Tuesday, April 27, 2021 | 2021 MarketBeat

Progyny, Inc. (NASDAQ:PGNY) EVP Jennifer Bealer sold 2,401 shares of the firm's stock in a transaction dated Friday, April 23rd. The stock was sold at an average price of $51.47, for a total transaction of $123,579.47. Following the completion of the sale, the executive vice president now owns 88,134 shares of the company's stock, valued at approximately $4,536,256.98. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jennifer Bealer also recently made the following trade(s):

  • On Tuesday, March 23rd, Jennifer Bealer sold 2,468 shares of Progyny stock. The stock was sold at an average price of $48.54, for a total transaction of $119,796.72.
  • On Tuesday, February 23rd, Jennifer Bealer sold 2,472 shares of Progyny stock. The stock was sold at an average price of $49.76, for a total transaction of $123,006.72.

Progyny stock traded up $1.66 during midday trading on Tuesday, reaching $57.56. The company's stock had a trading volume of 715,941 shares, compared to its average volume of 878,963. Progyny, Inc. has a fifty-two week low of $20.07 and a fifty-two week high of $57.99. The stock's 50 day simple moving average is $47.48 and its 200 day simple moving average is $41.17. The firm has a market capitalization of $5.02 billion, a PE ratio of 523.27 and a beta of 1.83.

Progyny (NASDAQ:PGNY) last released its earnings results on Wednesday, February 24th. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. Progyny had a return on equity of 7.43% and a net margin of 1.03%. The company had revenue of $100.30 million during the quarter. As a group, equities analysts predict that Progyny, Inc. will post 0.14 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Clearbridge Investments LLC increased its position in shares of Progyny by 0.4% in the fourth quarter. Clearbridge Investments LLC now owns 2,536,357 shares of the company's stock valued at $107,516,000 after buying an additional 10,135 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Progyny by 11.8% in the 4th quarter. BlackRock Inc. now owns 2,236,439 shares of the company's stock valued at $94,803,000 after acquiring an additional 235,442 shares during the last quarter. Brown Advisory Inc. increased its holdings in shares of Progyny by 0.8% in the 4th quarter. Brown Advisory Inc. now owns 1,326,771 shares of the company's stock valued at $56,242,000 after acquiring an additional 10,016 shares during the last quarter. GW&K Investment Management LLC grew its stake in Progyny by 27.3% during the 4th quarter. GW&K Investment Management LLC now owns 846,802 shares of the company's stock worth $35,896,000 after buying an additional 181,412 shares during the last quarter. Finally, Bamco Inc. NY lifted its holdings in shares of Progyny by 44.1% in the fourth quarter. Bamco Inc. NY now owns 588,279 shares of the company's stock valued at $24,937,000 after buying an additional 180,000 shares during the period. Institutional investors and hedge funds own 58.54% of the company's stock.

Several analysts have commented on the stock. Bank of America upgraded shares of Progyny from a "neutral" rating to a "buy" rating in a research note on Tuesday, March 16th. Zacks Investment Research lowered shares of Progyny from a "hold" rating to a "sell" rating in a research note on Saturday, February 27th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. The company presently has an average rating of "Buy" and a consensus price target of $37.71.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Article: Holder of Record

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: How are capital gains distributions different for tax-deferred account?


7 Bellwether Stocks Signaling a Return to Normal

Bellwether stocks are considered to be leading indicators about the direction of the overall economy, a specific sector, or the broader market. They are predictive stocks in that investors can use the company’s earnings reports to gauge economic strength or weakness.

The traditional definition of bellwether stocks brings to mind established, blue-chip companies. They are the home of mature brands with consumer loyalty. These may be stocks that aren’t associated with exceptional growth; some may be dividend stocks.

But there’s something different about normal this time around. If it’s true (and I think it is) that the old rules no longer apply, investors need to change the way they think about bellwether stocks. Plus, let’s face it, many stocks that we might consider to be bellwether stocks have already had a bit of a vaccine rally. That means that the easy gains are gone.

With that in mind, we’ve put together this special presentation that highlights seven of what may be termed the new bellwether stocks. These are stocks that investors should be paying attention to as the economy continues to reopen.

One quality of many of these stocks is that they are either negative for 2021 or underperforming the broader market. And that means that they are likely to have a strong upside as the economy grows.

View the "7 Bellwether Stocks Signaling a Return to Normal".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.